HUE042877T2 - Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal - Google Patents
Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommalInfo
- Publication number
- HUE042877T2 HUE042877T2 HUE13748243A HUE13748243A HUE042877T2 HU E042877 T2 HUE042877 T2 HU E042877T2 HU E13748243 A HUE13748243 A HU E13748243A HU E13748243 A HUE13748243 A HU E13748243A HU E042877 T2 HUE042877 T2 HU E042877T2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- pi13k
- optionally
- alpha
- pharmaceutical combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE042877T2 true HUE042877T2 (hu) | 2019-07-29 |
Family
ID=48980368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13748243A HUE042877T2 (hu) | 2012-08-07 | 2013-08-05 | Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal |
Country Status (39)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115786C2 (uk) * | 2012-08-07 | 2017-12-26 | Новартіс Аг | ФАРМАЦЕВТИЧНА КОМБІНАЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР B-Raf, ІНГІБІТОР EGFR ТА, НЕОБОВ'ЯЗКОВО, ІНГІБІТОР РІ3K-? |
| JP6449234B2 (ja) | 2013-03-21 | 2019-01-09 | ノバルティス アーゲー | 併用療法 |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| CN106574297B (zh) * | 2014-06-16 | 2020-07-21 | 环球创新网络公司 | 选择用于癌症治疗的个体化三联疗法的方法 |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| EP3380097A2 (en) * | 2015-08-28 | 2018-10-03 | Novartis AG | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
| JP2018525402A (ja) * | 2015-08-28 | 2018-09-06 | ノバルティス アーゲー | Ｐｉ３ｋ阻害剤のアルペリシブおよびｂ−ｒａｆ阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用 |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017210538A1 (en) | 2016-06-03 | 2017-12-07 | Giordano Caponigro | Pharmaceutical combinations |
| ES2974991T3 (es) | 2016-09-19 | 2024-07-02 | Novartis Ag | Combinaciones terapéuticas que comprenden un inhibidor de RAF y un inhibidor de ERK |
| FI3618875T3 (fi) | 2017-05-02 | 2023-07-04 | Novartis Ag | Raf-inhibiittoria ja trametinibia käsittävä yhdistelmähoito |
| KR20200036880A (ko) * | 2017-08-03 | 2020-04-07 | 노파르티스 아게 | 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물 |
| PL3860998T3 (pl) | 2018-10-05 | 2024-06-17 | Annapurna Bio Inc. | Związki i kompozycje do leczenia schorzeń związanych z aktywnością receptora apj |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| MX2021013817A (es) | 2019-05-13 | 2021-12-14 | Novartis Ag | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. |
| GB2629956A (en) * | 2022-01-27 | 2024-11-13 | Univ Tohoku | Therapeutic agent for cancer |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| IL319792A (en) * | 2022-09-26 | 2025-05-01 | Mapkure Llc | Combinations of B-RAF inhibitor and anti-EGFR antibody for cancer treatment |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
| WO2025262686A1 (en) * | 2024-06-20 | 2025-12-26 | Ilan Paz | Devices, systems and methods for optimized, personalized administration of oral dosage forms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| WO2008124161A1 (en) | 2007-04-10 | 2008-10-16 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2470898A4 (en) * | 2009-08-24 | 2013-03-13 | Genentech Inc | DETERMINATION OF THE SENSITIVITY OF CELLS FOR B-RAF HEMMER TREATMENT BY DETECTION OF KRAS MUTATIONS AND RTK EXPRESSION MIRRORS |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| BR112012008519A2 (pt) * | 2009-10-12 | 2016-04-05 | Glaxosmithkline Llc | combinação |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| CN103200943A (zh) * | 2010-11-08 | 2013-07-10 | 诺华有限公司 | 2-甲酰胺环氨基尿素衍生物在治疗egfr依赖性疾病或对靶向egfr家族成员的药剂有获得性耐受性的疾病中的应用 |
| JP2014533273A (ja) | 2011-11-10 | 2014-12-11 | メモリアル スローン−ケタリング キャンサー センター | ２−アミノ−４Ｈ−ナフト［１，２−ｂ］ピラン−３−カルボニトリルを用いた卵巣がんの治療 |
| MX354725B (es) * | 2011-11-11 | 2018-03-16 | Novartis Ag | Metodo de tratamiento de una enfermedad proliferativa. |
| UA115786C2 (uk) * | 2012-08-07 | 2017-12-26 | Новартіс Аг | ФАРМАЦЕВТИЧНА КОМБІНАЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР B-Raf, ІНГІБІТОР EGFR ТА, НЕОБОВ'ЯЗКОВО, ІНГІБІТОР РІ3K-? |
-
2013
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE042877T2 (hu) | Gyógyászati kombinációk egy B-Raf inhibitor, egy EGFR inhibitor és adott esetben egy PI13K-alfa inhibitor tartalommal | |
| HUS2100012I1 (hu) | 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók | |
| NL350117I2 (nl) | Metrafenon en mefentrifluconazool | |
| HUS2200034I1 (hu) | Glikokonjugációs eljárások és kompozíciók | |
| HUS2100032I1 (hu) | Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk | |
| HUE054881T2 (hu) | Nyomtatási rendszer és eljárás | |
| HUE040111T2 (hu) | Vegyületek és alkalmazási eljárásaik | |
| HUE037444T2 (hu) | ACC inhibitorok és azok felhasználása | |
| HUE036600T2 (hu) | ERK inhibitorok és alkalmazási eljárások | |
| HUE036739T2 (hu) | Vegyületek és eljárások kináz modulációra, és azok indikációi | |
| HUE037021T2 (hu) | DLL3- modulátorok és eljárások alkalmazásukra | |
| HUE071274T2 (hu) | Terminál és eljárás a terminál mûködtetésére | |
| HUE055072T2 (hu) | B-Raf gátlót és második gátlószert tartalmazó kombinációs terápia | |
| HUE042672T2 (hu) | Glifozát-rezisztens növények és kapcsolódó eljárások | |
| DK2854883T3 (da) | Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf | |
| HUE036461T2 (hu) | Vegyületek és eljárások kináz modulálásra, és indikációik | |
| HUE046559T2 (hu) | Policiklusos karbamoilpiridon vegyületek és gyógyszerészeti alkalmazásuk | |
| HUE054444T2 (hu) | Prolinnal lezárt kapcsos peptidek és felhasználásuk | |
| HUE040323T2 (hu) | PRMT5-inhibitorok és alkalmazásaik | |
| DK2906684T3 (da) | T-celle-modificerende forbindelser og anvendelser deraf | |
| HUE040427T2 (hu) | Nukleáris transzportmodulátorok és felhasználásuk | |
| EP2930714A4 (en) | Singing voice synthesizing system and singing voice synthesizing method | |
| HUE043861T2 (hu) | Módszerek és készítmények RNS-vezérelt célpont-DNS módosításra, és a transzkripció RNS-vezérelt modulálására | |
| HUE045379T2 (hu) | 3-ciklohexenil- és ciklohexil-szubsztituált indol- és indazolvegyületek, mint RORgammaT inhibitorok és felhasználásuk | |
| HUE058229T2 (hu) | Berendezés és eljárás hangobjektumok renderelésére |